Forte Biosciences is a clinical-stage, cancer-selective gene therapy company focused on developing product candidates designed to activate a patient's immune system against their own cancer. Co.'s cancer-selective gene therapy platform is built on Retroviral Replicating Vectors, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Co.'s gene therapy approach is designed to fight cancer through immunotherapeutic mechanisms of action without the autoimmune toxicities commonly experienced with other immunotherapies. The FBRX stock yearly return is shown above.
The yearly return on the FBRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FBRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|